Evolent Health, Inc. (EVH) Key Metrics

NYSE: EVHValuation, returns, debt and efficiency ratios over 10 years.

EVH valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$516.7M
Enterprise value
$1.26B
P/E (TTM)
—
Forward P/E
8.6
PEG ratio
1.93
Price / sales
0.2
10-yr median 1.8
Price / book
1.1
10-yr median 1.3
EV / EBITDA
185.4
10-yr median 43.0
Dividend yield
—
Beta
1.02

EVH key metrics, 2016–2025

Fiscal year ended December 31, 2025 · U.S. dollars

EVH valuation Price multiples at each fiscal year-end price.

Price / sales−51.8%
0.2
2025 · hover or tap a bar for each year
2016: 2.6 (−54.5%)2017: 1.8 (−30.6%)2018: 2.5 (+35.2%)2019: 1.1 (−55.9%)2020: 1.5 (+35.7%)2021: 2.6 (+78.1%)2022: 1.9 (−25.8%)2023: 1.9 (−3.9%)2024: 0.5 (−73.0%)2025: 0.2 (−51.8%)
20162025
Price / book−14.6%
1.1
2025 · hover or tap a bar for each year
2016: 0.7 (−15.1%)2017: 0.8 (+3.5%)2018: 1.3 (+71.5%)2019: 0.8 (−37.7%)2020: 2.2 (+171.9%)2021: 3.4 (+56.3%)2022: 3.1 (−10.8%)2023: 3.4 (+12.4%)2024: 1.3 (−62.6%)2025: 1.1 (−14.6%)
20162025
Price / free cash flow
96.1
2025 · hover or tap a bar for each year
2021: 173.02023: 32.32025: 96.1
20162025
Free cash flow yield+1.5 pts
1.0%
2025 · hover or tap a bar for each year
2016: −7.7% (−2.9 pts)2017: −7.1% (+0.6 pts)2018: −3.9% (+3.1 pts)2019: −10.5% (−6.6 pts)2020: −3.4% (+7.1 pts)2021: 0.6% (+3.9 pts)2022: −1.9% (−2.5 pts)2023: 3.1% (+5.0 pts)2024: −0.5% (−3.6 pts)2025: 1.0% (+1.5 pts)
20162025

EVH valuation history

Fiscal year-endToday10-year median

EVH returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

EVH debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

EVH cash returned to shareholders

DividendsBuybacksFree cash flow

EVH price vs earnings per share

Share price at year-endEPS (right axis)

EVH key metrics

2016–2025
Evolent Health, Inc. key metrics by fiscal year
2025202420232022202120202019201820172016
Valuation
Market capitalization$456.8M$1.29B$3.67B$2.63B$2.38B$1.36B$745.4M$1.54B$791.5M$666.5M
Enterprise value$1.29B$1.84B$4.13B$2.92B$2.40B$1.39B$1.01B$1.66B$674.5M$607.8M
Price / sales0.20.51.91.92.61.51.12.51.82.6
Price / book1.11.33.43.13.42.20.81.30.80.7
Price / free cash flow96.1—32.3—173.0—————
Price / operating cash flow11.868.825.8—61.5—————
EV / sales0.70.72.12.22.61.51.52.61.62.4
EV / EBITDA—23.0—66.743.0—————
EV / free cash flow272.3—36.3—174.1—————
Earnings yield−117.0%−4.8%−3.1%−0.7%−1.6%−24.6%−40.5%−3.4%−7.7%−24.0%
Free cash flow yield1.0%−0.5%3.1%−1.9%0.6%−3.4%−10.5%−3.9%−7.1%−7.7%
Dividend yield2.4%1.6%0.5%0.6%0.1%1.5%8.2%—0.0%0.0%
Shareholder yield (dividends + buybacks)11.2%2.8%0.9%1.0%0.1%2.7%8.6%0.1%0.2%0.1%
Share price at fiscal year-end$4.00$11.25$33.03$28.08$27.67$16.03$9.05$19.95$12.30$14.80
Per share
Revenue per share$16.43$22.28$17.65$14.43$10.55$10.89$8.34$8.11$6.76$5.64
Earnings per share−$4.68−$0.54−$1.02−$0.20−$0.44−$3.94−$3.67−$0.68−$0.94−$3.55
Operating cash flow per share$0.34$0.16$1.28−$0.12$0.45−$0.19−$0.52−$0.27−$0.43−$0.79
Free cash flow per share$0.04−$0.05$1.02−$0.53$0.16−$0.54−$0.95−$0.78−$0.87−$1.13
Cash per share$1.33$1.43$1.73$2.01$3.09$3.93$1.25$2.95$3.71$3.97
Book value per share$3.64$8.73$9.60$9.17$8.06$7.30$11.20$15.38$16.26$20.26
Tangible book value per share−$7.57−$7.12−$7.20−$3.27−$0.14$0.07$0.51$1.11$2.75$0.59
Dividends per share$0.10$0.18$0.17$0.16$0.02$0.24$0.74—$0.00$0.00
Capex per share$0.30$0.22$0.26$0.41$0.29$0.35$0.43$0.51$0.43$0.34
Debt per share$8.67$6.22$5.80$5.08$3.26$4.24$4.48$4.44$1.89$2.67
Shares outstanding114.2M114.7M111.3M93.7M86.1M84.9M82.4M77.3M64.4M45.0M
Change in shares outstanding−0.4%+3.1%+18.7%+8.9%+1.3%+3.1%+6.5%+20.2%+42.9%−2.4%
Returns & profitability
Return on equity (ROE)−75.5%−6.0%−11.7%−2.5%−5.7%−43.4%−28.6%−4.7%−6.2%−20.5%
Return on invested capital (ROIC)−0.2%−2.1%−4.2%0.3%−4.9%−22.6%−19.6%−3.4%−6.5%−27.8%
Return on assets (ROA)−24.1%−2.4%−5.0%−1.2%−2.6%−22.5%−18.8%−3.5%−4.8%−14.4%
Return on tangible assets−86.2%−8.5%−13.9%−2.9%−5.3%−38.8%−48.9%−8.5%−13.7%−50.8%
Free cash flow margin0.3%−0.2%5.8%−3.7%1.5%−4.9%−11.4%−9.6%−12.8%−20.1%
Financial health
Total debt$989.7M$713.7M$644.8M$476.1M$280.5M$359.8M$368.8M$343.6M$121.4M$120.3M
Cash & short-term investments$151.9M$163.5M$192.8M$188.2M$266.3M$333.4M$102.8M$228.3M$238.4M$178.9M
Net debt$837.8M$550.2M$452.0M$287.9M$14.2M$26.4M$266.0M$115.3M−$117.0M−$58.6M
Debt / equity2.380.710.600.550.400.580.400.290.120.13
Debt / assets0.520.280.240.260.200.240.250.200.090.10
Net debt / EBITDA—6.87—6.580.25—————
Current ratio1.310.851.011.101.181.361.193.322.852.01
Quick ratio1.310.851.012.061.872.461.972.792.872.32
Interest coverage-0.1-1.6-1.30.2-1.7-9.3-21.2-8.7-20.0-328.4
Working capital$121.1M−$108.4M$9.4M$44.6M$78.5M$144.4M$36.0M$341.2M$245.5M$133.0M
Invested capital$1.25B$1.55B$1.52B$1.15B$707.8M$646.0M$1.19B$1.30B$929.3M$853.5M
Tangible asset value−$864.2M−$816.2M−$800.9M−$306.1M−$12.4M$5.6M$48.5M$86.2M$176.9M$26.6M
Net current asset value−$977.7M−$936.0M−$928.9M−$479.8M−$201.9M−$307.2M−$340.2M−$45.0M$111.8M−$22.8M
Graham net-net per share−$9.54−$9.32−$9.75−$8.40−$5.99−$7.66−$5.87−$2.63$0.34−$2.19
Capital allocation
Dividends paid$11.1M$20.1M$18.8M$14.9M$1.3M$20.0M$61.1M—$0$0
Share buybacks (net)$40.0M$16.6M$15.3M$10.4M$0$17.4M$2.6M$1.2M$1.3M$365,000
Dividends + buybacks / free cash flow——29.9%—9.4%—————
Capex / revenue1.8%1.0%1.5%2.8%2.8%3.2%5.2%6.3%6.4%6.1%
Capex / operating cash flow87.8%132.7%20.2%—64.5%—————
Capex / depreciation0.290.210.230.570.420.480.580.890.860.90
Stock-based compensation / revenue2.1%1.6%2.1%2.5%1.8%1.6%2.3%2.8%4.7%8.9%
R&D / revenue——1.4%2.0%2.9%2.6%2.9%2.9%4.0%4.4%
SG&A / revenue16.2%10.3%18.2%18.2%24.2%44.4%57.2%48.8%47.3%63.2%
Efficiency
Days sales outstanding71.861.565.252.051.339.842.444.046.043.8
Days of inventory on hand——-50.5-127.6-209.1-155.9-25.541.9-29.7-71.8
Days payables outstanding17.912.012.827.035.518.265.5105.658.871.3
Cash conversion cycle (days)53.949.51.9-102.6-193.4-134.3-48.6-19.7-42.6-99.2
Receivables turnover5.085.935.607.027.129.168.608.297.948.33
Payables turnover20.4430.3228.5213.5110.2720.065.573.466.205.12
Inventory turnover———————8.71——
Asset turnover0.840.980.870.840.630.620.430.410.350.23
Average receivables$369.0M$430.7M$350.7M$192.6M$127.5M$100.9M$79.9M$75.6M$54.8M$30.5M
Average payables$77.9M$72.1M$52.7M$76.6M$64.0M$34.7M$92.1M$94.8M$43.4M$30.3M
Average inventory——−$208.0M−$362.1M−$376.7M−$297.6M−$35.8M$37.6M−$21.9M−$30.5M
Intangibles / total assets67.4%71.4%69.7%64.1%49.7%41.6%58.8%64.1%66.2%73.8%

Computed from EVH's annual financial statements (latest annual report filed February 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

EVH valuation and financial ratios

Evolent Health earned a return on equity of −75.5% and a return on invested capital of −0.2% in fiscal 2025. It ended the year with $989.7 million of debt and $151.9 million in cash and short-term investments, net debt of $837.8 million. It returned $51.1 million to shareholders: $11.1 million in dividends and $40.0 million in share buybacks. The share count rose 153.6% from 45.0M to 114.2M over 9 years.

See the EVH income statement, the EVH chart for price history, or the EVH stock overview for the latest quote and news.

EVH key metrics FAQ

What is Evolent Health's return on equity?

Evolent Health's return on equity (ROE) was −75.5% in fiscal 2025: net income of -$534.5 million on average shareholders' equity of $708.2 million.

What is Evolent Health's ROIC?

Evolent Health's return on invested capital was −0.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.

How much debt does Evolent Health have?

Evolent Health had total debt of $989.7 million at the end of fiscal 2025, a debt-to-equity ratio of 2.38.

What is Evolent Health's dividend yield?

Evolent Health paid $11.1 million in dividends in fiscal 2025 ($0.10 per share), a payout ratio of —.

Does Evolent Health buy back its shares?

Yes. Evolent Health spent $40.0 million on net share repurchases in fiscal 2025 Shares outstanding changed −0.4% over the year, to 114.2M..

What is Evolent Health's free cash flow yield?

Evolent Health generated $4.8 million of free cash flow in fiscal 2025, a free cash flow yield of 1.0% on its market value at year-end ($456.8 million).

What is Evolent Health's current ratio?

Evolent Health's current ratio was 1.31 at the end of fiscal 2025: current assets were 1.31 times current liabilities.

Health Information Services key metrics